Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $14.0B | $2.0B | $877M | $1.2B | 10.2% | 7.2% | 17.5% |
| 2024 | $13.0B | $1.8B | $746M | $1.1B | 9.3% | 7.0% | 78.5% |
| 2023 | $12.2B | $1.3B | $418M | $874M | 5.3% | 2.5% | -67.3% |
| 2022 | $11.9B | $2.0B | $1.3B | $1.5B | 12.7% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 11,863.90 | 12,161.60 | 13,008.90 | 13,951.70 |
| Operating Revenue | - | 11,863.90 | 12,161.60 | 13,066.90 | 13,974.70 |
| Cost Of Revenue | - | 8,155 | 8,796.70 | 9,384.50 | 9,939.20 |
| Gross Profit | - | 3,708.90 | 3,364.90 | 3,624.40 | 4,012.50 |
| Operating Expense | - | 1,956.70 | 2,241.20 | 2,486.40 | 2,496.30 |
| Selling General And Administration | - | 1,763.10 | 2,021.40 | 2,230 | 2,216.30 |
| Total Expenses | - | 10,111.70 | 11,037.90 | 11,870.90 | 12,435.50 |
| Operating Income | - | 1,752.20 | 1,123.70 | 1,138 | 1,516.20 |
| Total Operating Income As Reported | - | 1,436.50 | 725.60 | 1,086.70 | 1,384.70 |
| EBITDA | - | 1,954.40 | 1,345.80 | 1,811.30 | 2,012.70 |
| Normalized EBITDA | - | 2,262.60 | 1,715.10 | 1,840.30 | 2,129 |
| EBIT | - | 1,417.20 | 768.50 | 1,167.80 | 1,331.60 |
| Interest Expense | - | 179.80 | 199.60 | 208.30 | 224.10 |
| Net Interest Income | - | -179.80 | -199.60 | -208.30 | -224.10 |
| Other Non Operating Income Expenses | - | -32.20 | 15.50 | 60.20 | -55 |
| Other Income Expense | - | -335 | -355.20 | 29.80 | -184.60 |
| Interest Expense Non Operating | - | 179.80 | 199.60 | 208.30 | 224.10 |
| Net Non Operating Interest Income Expense | - | -179.80 | -199.60 | -208.30 | -224.10 |
| Pretax Income | - | 1,237.40 | 568.90 | 959.50 | 1,107.50 |
| Tax Provision | - | 233.90 | 188.50 | 212.40 | 229.80 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -58.26 | -122.24 | -6.41 | -24.07 |
| Net Income Continuous Operations | - | 1,003.50 | 380.40 | 747.10 | 877.70 |
| Net Income From Continuing And Discontinued Operation | - | 1,279.10 | 418 | 746 | 876.50 |
| Net Income From Continuing Operation Net Minority Interest | - | 1,002 | 379.20 | 746 | 876.50 |
| Net Income | - | 1,279.10 | 418 | 746 | 876.50 |
| Net Income Common Stockholders | - | 1,279.10 | 418 | 746 | 876.50 |
| Net Income Including Noncontrolling Interests | - | 1,280.60 | 419.20 | 747.10 | 877.70 |
| Normalized Income | - | 1,251.94 | 626.26 | 768.59 | 968.73 |
| Diluted NI Availto Com Stockholders | - | 1,279.10 | 418 | 746 | 876.50 |
| Basic Average Shares | - | 91.10 | 87.10 | 83.90 | 83.20 |
| Diluted Average Shares | - | 91.60 | 87.60 | 84.40 | 83.80 |
| Reconciled Depreciation | - | 537.20 | 577.30 | 643.50 | 681.10 |
| Reconciled Cost Of Revenue | - | 7,811.40 | 8,439.20 | 8,997.40 | 9,538.10 |
| Total Unusual Items | - | -308.20 | -369.30 | -29 | -116.30 |
| Total Unusual Items Excluding Goodwill | - | -308.20 | -369.30 | -29 | -116.30 |
| Minority Interests | - | -1.50 | -1.20 | -1.10 | -1.20 |
| Net Income Discontinuous Operations | - | 277.10 | 38.80 | 0 | 0 |
| Special Income Charges | - | -315.70 | -398.10 | -51.30 | -131.50 |
| Impairment Of Capital Assets | - | 261.70 | 349 | 5.30 | 4.30 |
| Restructuring And Mergern Acquisition | - | 54 | 49.10 | 46 | 127.20 |
| Gain On Sale Of Security | - | 7.50 | 28.80 | 22.30 | 15.20 |
| Depreciation Amortization Depletion Income Statement | - | 193.60 | 219.80 | 256.40 | 280 |
| Depreciation And Amortization In Income Statement | - | 193.60 | 219.80 | 256.40 | 280 |
| Earnings From Equity Interest | - | 5.40 | -1.40 | -1.40 | -13.30 |
| Amortization | - | 193.60 | 219.80 | 256.40 | 280 |
| Amortization Of Intangibles Income Statement | - | 193.60 | 219.80 | 256.40 | 280 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Labcorp Holdings Inc.this co. | LH | $21.4B | 24.41↑ premium | 2.48 | 10.2% | 13.61 |
| Mettler-Toledo International Inc. | MTD | $23.9B | 27.44 | - | -3676.8% | 20.87 |
| Insmed Incorporated | INSM | $22.7B | -17.81 | 30.77 | -172.8% | - |
| West Pharmaceutical Services, Inc. | WST | $22.4B | 45.41 | 7.06 | 15.5% | 28.40 |
| Quest Diagnostics Incorporated | DGX |
| - |
| - |
| - |
| - |
| - |
| $21.7B |
| 21.88 |
| 3.03 |
| 13.8% |
| 12.88 |
| STERIS plc | STE | $20.7B | 26.48 | 2.88 | 10.9% | 14.02 |
| Moderna, Inc. | MRNA | $20.5B | -7.25 | 2.37 | -32.6% | -7.54 |
| Incyte Corporation | INCY | $20.2B | 15.72 | 3.91 | 24.9% | 9.75 |
| Viatris Inc. | VTRS | $18.5B | - | 1.26 | -23.9% | - |
| Peer Median | - | 21.88 | 3.03 | -6.5% | 13.45 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Jul has averaged the highest return (+6.3%); Mar the lowest (-4.1%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.2%Positive MonthJan 2026: +8.23% | +6.5%Positive MonthFeb 2026: +6.48% | -7.7%Negative MonthMar 2026: -7.72% | -3.8%Negative MonthApr 2026: -3.75% | +1.3%Neutral MonthMay 2026: +1.27% | +7.7%Positive MonthJun 2026: +7.67% | +10.4%Positive MonthJul 2026: +10.43% | +6.9%*Positive MonthAug 2026: +6.87% | — | — | — | — |
| 2025 | +8.9%Positive MonthJan 2025: +8.93% | +0.5%Neutral MonthFeb 2025: +0.50% | -7.3%Negative MonthMar 2025: -7.29% | +3.6%Positive MonthApr 2025: +3.55% | +3.3%Positive MonthMay 2025: +3.30% | +5.4%Positive MonthJun 2025: +5.44% | -0.9%Neutral MonthJul 2025: -0.93% | +6.9%Positive MonthAug 2025: +6.89% | +3.3%Positive MonthSep 2025: +3.26% | -11.5%Negative MonthOct 2025: -11.53% | +5.8%Positive MonthNov 2025: +5.84% | -6.7%Negative MonthDec 2025: -6.66% |
| 2024 | -2.2%Negative MonthJan 2024: -2.20% | -2.9%Negative MonthFeb 2024: -2.91% | +1.2%Neutral MonthMar 2024: +1.22% | -7.8%Negative MonthApr 2024: -7.82% | -3.2%Negative MonthMay 2024: -3.21% | +4.4%Positive MonthJun 2024: +4.41% | +5.9%Positive MonthJul 2024: +5.86% | +6.7%Positive MonthAug 2024: +6.71% | -2.8%Negative MonthSep 2024: -2.79% | +2.1%Positive MonthOct 2024: +2.14% | +5.6%Positive MonthNov 2024: +5.65% | -4.9%Negative MonthDec 2024: -4.91% |
| 2023 | +7.1%Positive MonthJan 2023: +7.07% | -5.1%Negative MonthFeb 2023: -5.06% | -4.2%Negative MonthMar 2023: -4.15% | -1.2%Neutral MonthApr 2023: -1.18% | -6.3%Negative MonthMay 2023: -6.25% | +13.6%Positive MonthJun 2023: +13.55% | +3.2%Positive MonthJul 2023: +3.18% | -2.7%Negative MonthAug 2023: -2.73% | -3.4%Negative MonthSep 2023: -3.39% | -0.7%Neutral MonthOct 2023: -0.66% | +8.6%Positive MonthNov 2023: +8.60% | +4.8%Positive MonthDec 2023: +4.79% |
| 2022 | -13.6%Negative MonthJan 2022: -13.64% | -0.0%Neutral MonthFeb 2022: -0.04% | -2.8%Negative MonthMar 2022: -2.80% | -8.9%Negative MonthApr 2022: -8.87% | +2.7%Positive MonthMay 2022: +2.68% | -5.0%Negative MonthJun 2022: -5.01% | +11.9%Positive MonthJul 2022: +11.87% | -14.1%Negative MonthAug 2022: -14.08% | -9.1%Negative MonthSep 2022: -9.08% | +8.3%Positive MonthOct 2022: +8.32% | +8.5%Positive MonthNov 2022: +8.49% | -2.2%Negative MonthDec 2022: -2.17% |
| 2021 | — | — | — | — | +3.2%Positive MonthMay 2021: +3.24% | +0.5%Neutral MonthJun 2021: +0.50% | +7.4%Positive MonthJul 2021: +7.36% | +2.4%Positive MonthAug 2021: +2.44% | -7.2%Negative MonthSep 2021: -7.23% | +2.0%Neutral MonthOct 2021: +1.98% | -0.6%Neutral MonthNov 2021: -0.59% | +10.1%Positive MonthDec 2021: +10.12% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
